Before & after US election, I had sold out most of my stocks to reduce the risk and trim my portfolio. Most of my stocks were closed out with profits but offset by losses in some underperforming stocks like$センティーン (CNC.US)$,$ナイキ クラスB (NKE.US)$,$メルク (MRK.US)$and$セルシウス・ホールディングス (CELH.US)$. Both$エヌビディア (NVDA.US)$and$テスラ (TSLA.US)$are crucial in my portfolio for long term trading. I had added more positions in Tesla after US election because I believe Te...
This $2 Stock Remains Deeply Undervalued, Profitable in 2025, Offers 10x Upside within 20 Months Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns$バイキング・セラピューティクス (VKTX.US)$since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster. This unique biotech$エスペリオン・セラピューティクス (ESPR.US)$Esper...
メルクに関するコメント
Most of my stocks were closed out with profits but offset by losses in some underperforming stocks like $センティーン (CNC.US)$ , $ナイキ クラスB (NKE.US)$ , $メルク (MRK.US)$ and $セルシウス・ホールディングス (CELH.US)$ .
Both $エヌビディア (NVDA.US)$ and $テスラ (TSLA.US)$ are crucial in my portfolio for long term trading.
I had added more positions in Tesla after US election because I believe Te...
読み込み中...
Hugely Undervalued $2 Biotech With 21% Held Short $16 Price Target, Takeover Candidate, Soon Profitable. Fund that owns $バイキング・セラピューティクス (VKTX.US)$ since 2022 below $10 a share is also investing in ESPR and expects the company will be a block buster.
This unique biotech $エスペリオン・セラピューティクス (ESPR.US)$ Esper...
まだコメントはありません